Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 660 first isolates · URO · Febrile UTI / pyelonephritis · 2024-06-30 → 2025-06-29
UrologyNarrowest option reaching 80 % coverage, no active warning
meropenem 84 % (81 %–87 %)
Carbapenem: reserve for ESBL / critically ill patients.
Not covered: Enterococcus faecalis (10 %), Staphylococcus aureus (3 %), Staphylococcus saprophyticus (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
ciprofloxacin CIP
trend · Escherichia coli ⚠ Escherichia coli: 52 % resistant in the last 4 weeks (baseline 10 %)
74 %
54 %
n = 69
ceftriaxone CRO
trend · Escherichia coli ⚠ Active ESBL cluster (22 cases)
⚠ Escherichia coli: 50 % resistant in the last 4 weeks (baseline 5 %)
73 %
55 %
n = 69
⚠ Escherichia coli: 50 % resistant in the last 4 weeks (baseline 21 %)
67 %
55 %
n = 69
cefuroxime CXM
trend · Escherichia coli ⚠ Active ESBL cluster (22 cases)
⚠ Escherichia coli: 55 % resistant in the last 4 weeks (baseline 13 %)
66 %
49 %
n = 69
Most likely organisms for this profile
Escherichia coli
58 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
5 %
Pseudomonas aeruginosa
4 %
Staphylococcus aureus
3 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.